Table 1

A comparison of MOG-IgG CSF+/serum– patient characteristics between this study and the Oxford cohort from Jurynczyk et al

Clinical characteristicMOG-IgG CSF+/serum–
Jurynczyk et al
Age24, 6929±16.5
Female (%)10056
CSF MOG-IgG CBA score1, 4NA
Serum MOG-IgG CBA score0.75, 0.75NA
Time since onset (years)3, 4NA
Onset attack (%)
Unilateral ON025
Bilateral ON027
Transverse myelitis10020
Simultaneous ON and TM08
Disease course (%)
Endpoints (%)
VA ≤6/36016
Limiting walking distance507
Permanent bladder dysfunction5028
Permanent bowel dysfunction5020
  • ADEM, acute disseminated encephalomyelitis; CBA, cell-based assay; scored on a scale of 0 to 4; CSF, cerebrospinal fluid; MOG, myelin oligodendrocyte glycoprotein; NA, non-applicable; ON, optic neuritis; TM, transverse myelitis; VA, visual acuity.